Gossamer Bio, Inc. (GOSS)
CIK 1728117 · all EDGAR filings →
Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.
Shares outstanding over time
Latest: 488.8M shares as of Aug 8, 2026 (10-Q).⊙
Cash runway
Going-concern warning
auditor flagged substantial doubt
The company itself flagged going-concern doubt in a filing.
Full breakdown: cash runway tool
Warrants
| Tranche | Warrants | Exercise price | Term | Notes |
|---|---|---|---|---|
| Warrant | 199.9M | not tagged | — | — |
| Purchase Warrants | 135.8M | $0.34 | — | — |
| Prefunded Warrants | 33.4M | $0.0001 | — | — |
| Private Placement | 32.5M | not tagged | — | — |
Tranches exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.
Warrants outstanding: 30.7M underlying shares, as reported Dec 31, 2025 (10-K).
Reported exercise price: $2.04 (aggregate figure as tagged; individual tranches vary).
Rough fully diluted estimate: 519.5M = 488.8M O/S + 30.7M warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.
Convertible notes
| Note | Principal | Carrying | Conv. price | Rate | If converted |
|---|---|---|---|---|---|
| Two Thousand Twenty Seven Notes | $181.1M | $18.9M | $16.23 | 5% | ~11.2M sh |
| Convertible Senior Notes Due 2030 | not tagged | $65.2M | not tagged | 7.5% | — |
If every note above converted at its tagged price: ~11.2M new shares on 488.8M currently outstanding. An estimate from principal ÷ conversion price, with inputs carrying different as-of dates; make-whole adjustments, capped calls and partial repurchases are not modeled.
Notes exactly as the company dimensioned them in its 10-Q filed Aug 13, 2026 →. Principal is face amount as tagged, not what remains after repurchases unless the filer updated the tag. A note the filer did not dimension is absent here, not absent from the balance sheet; the exhibits stay the ground truth.
Fully diluted build-up
Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.
| Shares outstanding | 488.8M | Aug 8, 2026 |
| + Warrant (if exercised) | 199.9M | Jun 30, 2026 |
| + Purchase Warrants (if exercised) | 135.8M | Jun 30, 2026 |
| + Prefunded Warrants (if exercised) | 33.4M | Jun 30, 2026 |
| + Private Placement (if exercised) | 32.5M | Jun 30, 2026 |
| + Two Thousand Twenty Seven Notes (if fully converted) | 11.2M | Jun 30, 2026 |
| Fully diluted estimate | 901.5M | +84.4% vs O/S |
Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.
Registrations and offerings
Last 12 months: 2 executed · 1 registered.
Full history and shelf status: offering checker · S-3 shelf checker
Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.
Keep going: float checker · offering calendar · short-squeeze screener · full GOSS workspace